Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia.
We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.
Hung
G-Y
GY
Department of Pediatrics, Taipei Veterans General Hospital, Tapei, Taiwan, ROC.
Chiou
T-J
TJ
Hsieh
Y-L
YL
Chen
P-M
PM
Hwang
B
B
D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000379:methods*; D002675:Child, Preschool; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D009918:Orbital Neoplasms / Q000628:therapy*; D023981:Sarcoma, Myeloid / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D014178:Translocation, Genetic; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods
D007166:Immunosuppressive Agents